STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Journal of Hepatology

Volumn 62, Issue 6, 2015, Pages 1246-1255

  Ferenci, Peter ^a   Asselah, Tarik ^b   Foster, Graham R ^c   Zeuzem, Stefan ^d   Sarrazin, Christoph ^d   Moreno, Christophe ^e   Ouzan, Denis ^f   Maevskaya, Marina ^g   Calinas, Filipe ^h   Morano, Luis E ⁱ   Crespo, Javier ^j   Dufour, Jean François ^k   Bourlière, Marc ^l   Agarwal, Kosh ^m   Forton, Daniel ⁿ   Schuchmann, Marcus ^o   Zehnter, Elmar ^p   Nishiguchi, Shuhei ^q   Omata, Masao ^r   Kukolj, George ^s   Datsenko, Yakov ^t   Garcia, Miguel ^s   Scherer, Joseph ^s   Quinson, Anne Marie ^s   Stern, Jerry O ^s   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BEAUJON HOSPITAL   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e ERASME HOSPITAL   (Belgium)

^f INSTITUT ARNAULT TZANCK   (France)

^g PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^h Universidade de Lisboa   (Portugal)

ⁱ HOSPITAL DO MEIXOEIRO   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k UNIVERSITY OF BERN   (Switzerland)

^l HÔPITAL SAINT JOSEPH   (France)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ ST GEORGE S HOSPITAL   (United Kingdom)

^o UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^p Private Practice   (Germany)

^q HYOGO COLLEGE OF MEDICINE   (Japan)

^r Yamanishi Central and Kita Hospitals ^*  (Japan)

^s BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^t BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

Clinical trial; DAA; Early treatment success; NS3 4A protease inhibitor; Phase 3; SVR12

Indexed keywords

BOCEPREVIR; FALDAPREVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-((CYCLOPENTYLOXY)CARBONYL)-3-METHYLVALYL-4-((8-BROMO-7-METHOXY-2-(2-((2-METHYLPROPANOYL)AMINO)-1,3-THIAZOL-4-YL)QUINOLIN-4-YL)OXY)-N-(1-CARBOXY-2-ETHENYLCYCLOPROPYL)PROLINAMIDE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INFECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; THIAZOLES;

EID: 84925873726     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.12.024     Document Type: Article

References (38)

1. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
2. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
4. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. US Food and Drug Administration (FDA). Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (Incivek combination treatment): drug safety communication - serious skin reactions. < http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm332860.htm >; 2012 [accessed 06.14].
6. Janssen Cilag International NV. INCIVO™ (telaprevir) Summary of product characteristics. < http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf >; 2013 [accessed 06.14].
7. Vertex Pharmaceuticals Incorporated. INCIVEK™ (telaprevir) Highlights of US prescribing information. < http://pi.vrtx.com/files/uspi-telaprevir.pdf >; 2013 [accessed 06.14].
8. Merck & Co., Inc. VICTRELIS™ (boceprevir) Summary of product characteristics. < http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002332/human-med-001464.jsp&mid=WC0b01ac058001d124&jsenabled=true >; 2013 [accessed 06.14].
9. Merck & Co., Inc. VICTRELIS™ (boceprevir) Highlights of US prescribing information. < http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf >; 2014 [accessed 06.14].
10. M. Llinas-Brunet, M.D. Bailey, N. Goudreau, P.K. Bhardwaj, J. Bordeleau, and M. Bös Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) J Med Chem 53 2010 6466 6476
11. P.W. White, M. Llinas-Brunet, M. Amad, R.C. Bethell, G. Bolger, and M.G. Cordingley Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob Agents Chemother 54 2010 4611 4618
12. M.P. Manns, M. Bourliere, Y. Benhamou, S. Pol, M. Bonacini, and C. Trepo Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection J Hepatol 54 2011 1114 1122
13. M.S. Sulkowski, T. Asselah, J. Lalezari, P. Ferenci, H. Fainboim, and B. Leggett Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
14. M.S. Sulkowski, M. Bourliere, J.P. Bronowicki, T. Asselah, J.M. Pawlotsky, and S.D. Shafran Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial Hepatology 57 2013 2155 2163
15. S. Nishiguchi, Y. Sakai, M. Kuboki, S. Tsunematsu, Y. Urano, and W. Sakamoto Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection Liver Int 34 2014 78 88
16. D. Dieterich, T. Asselah, D. Guyader, T. Berg, M. Schuchmann, and S. Mauss SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients Antimicrob Agents Chemother 58 2014 3429 3436
17. Sabo JP, Kort J, Haschke M, Ballow C, Girlich B, Feifel U, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. In: 2013 Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, Georgia, USA. 3-6 March, 2013. Abstract 35.
18. L. Castera, X. Forns, and A. Alberti Non-invasive evaluation of liver fibrosis using transient elastography J Hepatol 48 2008 835 847
19. M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, and F. Kazemi Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 2005 48 54
20. M. Friedrich-Rust, M.F. Ong, S. Martens, C. Sarrazin, J. Bojunga, and S. Zeuzem Performance of transient elastography for the staging of liver fibrosis: a meta-analysis Gastroenterology 134 2008 960 974
21. L. Castera Noninvasive methods to assess liver disease in patients with hepatitis B or C Gastroenterology 142 2012 1293 1302
22. J. Chen, J. Florian, W. Carter, R.D. Fleischer, T.S. Hammerstrom, and P.R. Jadhav Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies Gastroenterology 144 2013 1450 1455
23. US Food and Drug Administration (FDA). Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0, December, 2004; clarification August 2009. < http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf >; 2009 [accessed 06.14].
24. HCV Phenotype Working Group, HCV Drug Development Advisory Group. Clinically relevant HCV drug resistance mutations figure and tables. Ann Forum Collab HIV Res 2012;14:1-10
25. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, and V.V. Rafalsky Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
26. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.P. Bronowicki, and P. Andreone Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679
27. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, and Y. Horsmans Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
28. C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
29. P. Ferenci, and G. Dusheiko Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis Gut 63 2014 1033 1034
30. R.S. Sane, G.G. Steinmann, Q. Huang, Y. Li, L. Podila, and K. Mease Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients J Pharmacol Exp Ther 351 2014 403 412
31. M.T. Huisman, J. Snoeys, J. Monbaliu, M.A. Martens, V.J. Sekar, and A. Raoof In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters Hepatology 52 2010 123A
32. P. Ferenci, R. Aires, K.L. Beavers, M. Curescu, P.R. Abrão Ferreira, and M. Gschwantler Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients Hepatol Int 8 2014 83 93
33. Jacobson IM, Asselah T, Ferenci P, Foster GR, Jensen DM, Negro F, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon α-2a and ribavirin in treatment-experienced patients with chronic HCV genotype-1 infection. Hepatology (AASLD) 2013;58:Abstract 1100.
34. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, A.W. Lohse, and B. Müllhaupt Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
35. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
36. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. < http://www.hcvguidelines.org > [accessed 10.14].
37. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, and M. Puoti Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
38. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, and A. Correqidor Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765